Auris, nasus, larynx · 2007
Early assessment of clinical response to concurrent chemoradiotherapy in head and neck carcinoma using fluoro-2-deoxy-d-glucose positron emission tomography.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Horiuchi Choichi, Taguchi Takahide, Yoshida Takafumi, Nishimura Goshi, Kawakami Mariko, Tanigaki Yuji, Matsuda Hideki, Mikami Yasukazu, Oka Takashi, Inoue Tomio, Tsukuda Mamoru
Аннотация
OBJECTIVES: The aim of this study is to assess the utility of FDG-PET in the evaluation of therapeutic effects at 4 weeks after the completion of the concurrent chemoradiotherapy (CCR) in patients with head and neck squamous cell carcinoma (HNSCC).
METHODS: Thirty-one patients with previously untreated HNSCC were retrospectively investigated about FDG-PET, CT, MRI and biopsies of the carcinoma before and 4 weeks after the treatment.
RESULTS: The results of pathological examinations after CCR showed 6 residual cases and 25 ones with a pathologically complete response (pCR). The specificity of FDG-PET was 80%, although the sensitivity was limited to 67%.
CONCLUSIONS: FDG-PET has a high specificity but limited sensitivity to discriminate residual cancer from fibrosis or scar at 4 weeks after CCR. FDG-PET at 4 weeks after CCR was too early to perform because of limited sensitivity.
METHODS: Thirty-one patients with previously untreated HNSCC were retrospectively investigated about FDG-PET, CT, MRI and biopsies of the carcinoma before and 4 weeks after the treatment.
RESULTS: The results of pathological examinations after CCR showed 6 residual cases and 25 ones with a pathologically complete response (pCR). The specificity of FDG-PET was 80%, although the sensitivity was limited to 67%.
CONCLUSIONS: FDG-PET has a high specificity but limited sensitivity to discriminate residual cancer from fibrosis or scar at 4 weeks after CCR. FDG-PET at 4 weeks after CCR was too early to perform because of limited sensitivity.
Предметные рубрики MeSH
AdultAgedAntineoplastic Combined Chemotherapy ProtocolsBiopsyBlood GlucoseCarcinoma, Squamous CellCell SurvivalCombined Modality TherapyFemaleFluorodeoxyglucose F18Follow-Up StudiesHumansMagnetic Resonance ImagingMaleMiddle AgedNeoplasm StagingNeoplasm, ResidualOtorhinolaryngologic NeoplasmsPositron-Emission TomographyPrognosisRadiotherapy DosageSensitivity and SpecificityTomography, X-Ray ComputedTreatment Outcome